Investigating how amyloid beta proteins assemble in the brain under natural conditions
Official title: Nanoscale assembly of amyloid oligomers at physiologically relevant conditions
Funded at University of Nebraska Medical Center · NIH-10932919 · Data updated 2026-11-12
This study is looking at how certain proteins related to Alzheimer's disease come together in the brain and how the brain's cell membranes might help this process, which could lead to new ways to treat the early stages of Alzheimer's for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | September 25, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $428,073 |
| NIH project number | 5R01GM148537-02 |
| Project ID | NIH-10932919 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for Alzheimer's disease, particularly those showing early signs of cognitive decline or changes in lipid metabolism.
✕Less likely to help
Patients with advanced Alzheimer's disease or those not exhibiting any cognitive decline may not benefit from this research.
What this research studies
This research focuses on understanding how amyloid beta (Aβ) proteins, which are linked to Alzheimer's disease, assemble into aggregates at concentrations that are relevant to the human brain. The study uses a novel approach that examines the role of cell membranes in facilitating this assembly process, particularly at low concentrations of Aβ. By exploring how changes in membrane composition influence the formation of these aggregates, the research aims to uncover new insights into the mechanisms of Alzheimer's disease development. Patients may benefit from this research as it could lead to new therapeutic strategies targeting the early stages of Alzheimer's.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or slow the progression of Alzheimer's disease.
How similar studies have gone: While the approach of studying amyloid beta assembly at physiologically relevant concentrations is relatively novel, similar research has shown promise in understanding Alzheimer's pathology.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Lyubchenko, Yuri L — University of Nebraska Medical Center
- Study coordinator: Lyubchenko, Yuri L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.